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Who is responsible for your health: is it you, your doctor or 
the new technologies? 
 
Vincenzo Atella
1
 and Francesco D’Amico1,2 
 
Abstract 
The aim of the paper is to disentangle the roles that patients, physicians and technology can have on 
patient health outcomes. The analysis focuses on patients suffering from hypercholesterolemia. Using a 
large and detailed dataset of patients collected by the Italian College of General Practitioners (SIMG) 
over the period 2001–2006, we observe the existence of heterogeneity in the time needed to reach an 
optimal level of health stock. We firstly explore whether patients recovering faster exhibit lower 
hospitalization rates. Secondly, we study the determinants of the speed of recovery to a good health 
status. Results suggest that a 10 % increase in the speed of recovery reduces hospitalization rates by 1 
% in the general sample and by 1.25 % in patients in primary prevention. Furthermore, we show that 
recovering to a good health status is a multifaceted phenomenon, with technology explaining from 54 
to 68 % of the total effect. 
 
 
 
1. Introduction 
Patient health outcomes are complex phenomena and disentangling empirically their 
determinants is an ever more complex task arising from the interplays of three 
important factors: the patient, the physician and the available technologies. In fact, a 
valid diagnosis from a physician will not have the hoped for effect if effective 
treatments are not available. Similarly, the availability of effective treatments would 
not lead to a health improvement if physicians do not properly match diseases and 
treatments. Finally, patients should be compliant to physician recommendations in 
order to reach a good health outcome. Despite its importance from a policy 
perspective, no study to our knowledge has ever tried to disentangle and empirically 
measure the different roles that these actors jointly play on health outcomes.  
In our view, what has prevented researchers to succeed in this task is the lack of a 
sufficient level of clinical and socio-demographic details when using “micro” data, 
even for those studies that adopt a disease-specific approach [1-3]. Furthermore, 
objective measures of health outcomes are needed. Finally, to be informative, the 
analyses should be conducted at population, or on samples representative of the 
population (such as those used in clinical trials). Clearly, this is a highly data 
demanding approach, requiring information on patient health profiles at the beginning 
of the observation period (initial conditions), on the treatments, on the events to 
which they have been exposed over time, and on the physician treatment strategies. 
Ideally, this implies adopting an investigation strategy similar to that used in 
randomized clinical trials, but extended to the population. 
We try to fill this gap by disentangling and measuring the contribution that each 
of the above mentioned factors can have on the health outcomes of a large 
representative population of Italian patients suffering from hypercholesterolemia and 
treated with statins. While this research focuses on a particular health condition, the 
model we introduce in the following sections has the potential to be adapted to study 
other health problems and diseases for which there exists a measurable health target.  
We decided to focus on hypercholesterolemia because it represents a particularly 
interesting condition to analyze, for at least three reasons. Firstly, over the last 10 
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years there has been a growing public concern about high levels of cholesterol in the 
population that may have changed patient awareness about the problem, influencing 
their behavior (mainly through changes in compliance rates) over time.  Secondly, 
although over the last 20 years the entire drug industry has witnessed a substantial 
technical advancement, statins represent a class of drugs which has shown a 
substantial improvement over time in its efficacy to lower cholesterol. Last but not 
least, new guidelines to treat cholesterol have been introduced in recent years, 
challenging doctors to continuously adapt their patient management strategies to the 
new evidence based medicine. 
Compared to previous literature, we then further innovate by addressing a 
different and more important question for patient health status. Instead of exploring 
the determinants of patient health stock [4-8], we focus on the “time needed” to 
recover to an optimal level of health and on its determinants. Providing evidence on 
this issue has important policy implications beyond the specific case under 
investigation, given that a longer patient exposure to adverse health shocks (i.e., high 
levels of cholesterol) may results in future negative health outcomes, such as 
hospitalization, invalidity and death. Therefore, we will firstly explore whether 
patients with a faster recovery (i.e., lower exposure to high cholesterol levels) exhibit 
lower hospitalization rates for Cardio-Vascular Diseases (CVDs). Then, we will 
analyze the determinants of their speed of recovery.  
The analysis is based on the Health Search Database [9], which is collected by 
GPs on a large sample of the Italian population. Unlike standard registry datasets, 
these data provide information on a richer set of patient characteristics that allows us 
to disentangle the beneficial effects of new technologies (more effective drugs) from 
i) patient compliance to medication, ii) physicians’ ability to manage the disease 
(“process” innovation) and iii) standard confounding problems deriving from a 
patient’s past clinical history.  
The paper is organized into six sections. Section two presents some stylized facts 
about cholesterol trends. Section three introduces the methodology used to define and 
construct our objective health status indicator. Section four presents the data, the 
sample selection process and the steps followed to construct the variables of interest. 
Section five shows the main results and discusses the policy implications. In 
particular, we provide quantitative evidence on how the speed of recovery can affect 
hospitalization rates for CVDs and then we measure the role of each single factor on 
the speed of recovery. Finally, conclusions are drawn in section six. 
 
2. Cholesterol trends and the role of statins: Some stylized facts and a puzzle. 
Panel A in Figure 1 reports the trends in “Total” and “Low-Density Lipoprotein” 
(LDL) cholesterol levels for the patients included in Health Search, a nationally 
representative database managed by the Society of the Italian College of General 
Practitioners (SIMG). As we can see, both measures of cholesterol levels are 
decreasing. Furthermore, in panel B we observe the cholesterol level distributions 
over time, which show a movement toward the left (a reduction in average levels) as 
well as a shrinking of the distribution shape. This second aspect is important as it 
proves that in Italy not only the LDL average, but also its variability is reducing.  
A more interesting phenomenon that emerges from these data is reported in Table 
1 and in Figure 2, where LDL cholesterol level trends are split by patient cohorts 
according to their initial year of treatment. A number of interesting results emerge 
from the table: 
1. The average starting level of LDL lowers across cohorts (Table 1, Panel 
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A). This is consistent with the update of cholesterol guidelines in Italy 
over time, progressively including patients with lower blood lipid levels 
in the treatment protocol, thus moving toward a more preventive 
approach to dyslipidemia;  
2. The speed at which cholesterol levels reduce over time has increased 
(Table 1, Panel B); 
3. Patients who started the therapy earlier are likely to converge to a 
“higher” level of cholesterol over a “longer” period of time. This 
phenomenon appears regularly throughout all cohorts in our sample (all 
trajectories intersect); 
4. On average, older cohorts do not reach the LDL cholesterol target of 120 
mg/dl. 
 
While the first two results can be easily understood based on changes in 
guidelines over time, the last two results are somehow counter-intuitive, since we 
would expect that longer treatment periods would be conducive to better health 
outcomes. A possible explanation is that new and more effective chemical compounds 
(the so called “second-generation statins”) have been marketed and prescribed in Italy 
over the period of our investigation, reducing cholesterol levels. Furthermore, the 
introduction in 2004 of larger pack-sizes (28-30 vs. 14 tablets per package), may have 
affected patient behavior by improving adherence to the treatment, thus leading to 
better cholesterol management. However, these two factors alone can hardly explain 
the different cohort patterns reported in Table 1-Panel B, given that new active 
ingredients and larger pack-sizes are supposed to be available to all patients, 
irrespective of the cohort to which they belong. 
In our view, a plausible explanation for such cholesterol reduction patterns across 
cohorts may be found in physician behaviors in treating cholesterol. We believe that 
GPs who see their patients responding well to an existing therapy, could decide not to 
update it even when new protocols are available or newer compounds are introduced. 
If this was the case, it could be motivated by prudential attitudes, aimed to avoid any 
potential side-effects as a consequence of the adoption of newer drugs or of higher 
dosages. Symmetrically “newcomer” patients are more likely to be treated with the 
most recent drugs, in absence of a past treatment.  
Under these assumptions, the presence of technical change (both in terms of 
process and products) could then contribute to create a gap in health outcomes for 
earlier and longer-lasting treated patients compared to “newcomer” patients. 
 
3. The definition and measurement of the health indicator. 
In this section we define our indicator of objective health status. One of the 
implications of the Grossman model [10] is that health is an inherited durable capital 
stock that depreciates over time. Therefore, investment in health can be seen as an 
activity where medical care is combined with other inputs in order to produce new 
health to partly counteract the natural deterioration of the health shocks. Thus, the 
demand for health care can be considered as a derived demand for goods and services 
to preserve the inherited stock of health (HSi,t) and/or to further achieve a desired 
stock of health (HS
*
i,t). Following Grossman, the i-th patient’s health status at time t 
can be represented by a partial adjustment model: 
 
 HSi,t = HSi,t-1 +  (HS
*
i,t - HSi,t-1) - iHSi,t-1    (1) 
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where i>0 is the health stock depreciation rate and  0≤≤1 represents the “speed” at 
which individuals are able to achieve their target value. If patients reach their goal in 
one period then λ=1, while if their health status remains unchanged or even reduces, 
then λ=0 or it becomes negative.  
In the empirical literature λ has always been considered as an “average” parameter 
to be estimated. Our aim in this research is to look at λ as a measurable variable and 
then to further understand its determinants. In order to achieve this goal, we make two 
simplifying assumptions that, without loss of generality, help designing the empirical 
procedure.   We assume that health status for hypercholesterolemic patients is 
function of the LDL level alone (HSi,t = f(LDLi,t)), with the first derivative being 
negative (i.e. HSi,t / LDLi,t<0). 
 
Based on these two assumptions,  eq. (1) can be rewritten as: 
 
 f(LDLi,t)= f(LDLi,t-1) + [f(LDL
*
i)– f(LDLi,t-1)] - if(LDLi,t-1)  (2) 
 
with 
 LDL
*
i = f(ri)        (3) 
 
The optimal level of LDL cholesterol (LDL
*
i) is patient specific, time-independent 
and is function of the individual cardiovascular risk-index (ri).
3
  
In order to derive an analytical formulation of , we solve the equation (2) to 
obtain: 
 
 i,t =  [Δf(LDLi,t) + if(LDLi,t-1)] / Δf(LDL
*
i,t) =  
 
     = Δ’f(LDLi,t) / Δf(LDL
*
i,t)      (4) 
 
where Δf(LDLi,t) = f(LDLi,t) – f(LDLi,t-1) represents the difference between the current 
and the previous health status and Δf(LDL*i,t) = f(LDL
*
i,t) – f(LDLi,t-1) is the health gap 
that still needs to be recovered at time t through medical treatment and healthy 
behaviors. From an empirical point of view the term Δ’f(LDLi,t) represents the 
absolute variation in the health stock expressed as a function of the LDL level. 
The definition of i,t which stems from eq. (4) has an appealing clinical 
interpretation. In fact, although researchers cannot usually observe the single 
components that characterize the numerator in eq. (4), they can be interpreted as 
patient “good behavior” (Δf(LDLi,t)) and “bad behavior” (if(LDLi,t-1)) in achieving the 
therapeutic goals. This interpretation can be better understood by looking at the graph 
in figure 3, where we observe two different hypothetical paths of LDL cholesterol 
towards the target (LDL
*
). The blue line represents the behavior of a patient whose net 
investment is characterized only by “good behavior”, while the black line represents 
the behavior of a patient who alternates periods of “good behavior” with periods of 
“bad behavior” (identified by those periods in which ΔLDLi,t>0 and therefore ΔHSi,t = 
HSi,t-HSi,t-1 = Δf(LDLi,t) ≤ 0). It is clear that the speed at which the first patient reaches 
                     
3 The cardiovascular risk index represents the individual predicted risk at time t to incur in a CVD 
during the following 10 years on the basis of the assessed current health and life-style profile [10]. This 
index summarizes various patient characteristics including age, gender, smoking habits, clinical 
conditions, genetic factors and any previous experiences of CVD events. 
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the target is greater than the speed of the second patient.
4
 In particular, individuals 
who diverge from full health will present a negative value of , while individuals who 
converge will show a positive value. For instance, let’s assume that Patient A’s 
optimal LDL level is 120 mg/dl and that their level at t-1 is 200 mg/dl. Let’s also 
assume that Patient A’s LDL level reduces to 180 mg/dl at time t. In this case, their  
value attained would be equal to (200-180)/(200-120)=0.25. The same formula would 
apply also if their LDL increases, leading however to a negative value of . 
In this model we assume that HSi,t=f(LDLi,t)=1/LDLi,t, as it represents a simple 
functional form that produces an inverse relation between health and LDL.  However, 
other functional specifications are equally suitable (e.g. HSi,t = -LDLi,t). In the 
empirical analysis we have run sensitivity tests using different specifications of the 
functional relationship and found that alternative functional forms do not alter our 
final results.  
 
4. Data and descriptive statistics. 
Our empirical analysis is based on data collected in the Health Search Database 
(HSD), a longitudinal observational database run by the Italian College of General 
Practitioners (SIMG – Società Italiana di Medicina Generale) since 1998. The HSD 
contains data from computer-based patient records from General Practitioners (GPs) 
throughout Italy. Participation is on a voluntary base, although the distribution of GPs 
tends to replicate the regional organization of the NHS [9].  
Patient data are linked through a unique anonymous identifier to drug 
prescriptions, clinical events and diagnoses, hospital admissions and causes of death. 
It contains patient-level information on prescriptions such as dispensing date, drug 
information and the general practitioner recommended dosage (GPRD). It also 
includes hospitalization status by primary Diagnosis Related Groups, information on 
patients' clinical histories, on co-payment exemptions and a set of socio-demographic 
indicators. 
Up to December 31
st
 2006, the dataset contained information collected by 796 
GPs for a total of 1,532,357 patients. Our analysis is based on information gathered 
by those 400 GPs who guaranteed a high data quality according to a specific 
algorithm developed by the Health Search team [9, 13]. This algorithm selects GPs on 
the basis of their capacity to provide completeness of information in terms of patient 
clinical and vital characteristics (for instance smoking status, height, weight) and in 
terms of diagnostic tests results, diagnoses and other medical conditions. 
From this sample we have extracted patient identifiers using two main inclusion 
criteria:  
i) age between 39 and 70 at the time of their first appearance in the HSD (people 
using statins before their forties are often receiving them for reason other 
than hypercholesterolemia). 
ii) received a prescription of statins at any point over the 2001-2006 period.  
These criteria have produced a sub-sample of 42,140 patients. We have then 
dropped observations on the first quarter of 2001 (to avoid the risk of including non-
incident patients) and those patients who started the treatment only in 2006 as their 
follow-up time would have been less than one year. 
The original GP registry information has then been collapsed into quarterly 
statistics. The use of quarters as time unit seems reasonable in order to minimize the 
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Equation 4, reconciling the economic and the clinical perspective. 
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number of zero occurrences in drug consumption and to preserve the dynamic aspect 
of the model. More importantly, clinical evidence shows how statins may produce 
most of their effects simply after one quarter of use. 
The final sample is a quarterly panel of individuals observed over the period 
2002-2006. This dataset is balanced in terms of GPs (400), but unbalanced in terms of 
patients (4,290 patients, for a total of 21,188 observations). We compute the optimal 
LDL value for each patient as function of the individual’s cardio-vascular risk (ri,t) 
according to eq. 3. We define three different risk categories: low risk (0%≤ ri,t≤5% 
and no past CVD events), medium risk (5%≤ ri,t≤10% and no past CVD events) and 
high risk (ri,t>10%, which includes all the individuals with any past CVD event)
5
. 
According to international guidelines, LDL needs to be lower than 120 mg/dl for low-
risk patients, below 100 mg/dl for medium-risk patients, and under the level of 80 
mg/dl for high-risk patients. 
Table 2 reports the descriptive statistics. As we can see, the average value of i,t 
over the whole period is just above 0.1, meaning that patients take almost 10 quarters 
on average to reach the LDL* target.  
The sample is balanced in terms of gender with more than 70% of the individuals 
over 60 years old. Atorvastatin and Simvastatin determine more than 60% of the 
prescriptions, the average daily dosage prescribed being close to 27 mg. About 60% 
of the patients suffer from hypertension and 29% have diabetes. 9% are in secondary 
prevention, meaning that they have experienced at least one CVD in the past, as 
opposed to primary prevention, when the individual has not experienced any CVD 
related event.  Most of our sample is made up of patients who started treatment in 
2002. Treatment starting year for our purposes defines as a “cohort”.  
Table 3 shows descriptive statistics by cohort of treatment. Speed of recovery 
(has sharply and monotonically increased by starting year, with the 2002 cohort 
recording the lowest value (11% or about 10 quarters) and the 2005 cohort reporting 
the highest value (38% or about 2.5 quarters).  
 
5. Empirical results. 
 
5.1 – The effect of the speed of recovery on hospitalization rates. 
In this section we explore whether the speed of recovery () has any impact on the 
CVD hospitalization probability by using a probit model. From a methodological 
perspective, we examine the probability of hospitalization over a two-year period 
starting from the first appearance of the patient in the dataset. A two-year time 
window is adequate as it allows us to observe a uniform time period for all cohorts, 
including patients who started treatment in 2005. We include in this analysis only 
those patients for whom a full set of information was available for at least two 
consecutive years since their first appearance. The final sample consists of 3,316 
observations. We consider a two-year period an effective compromise: a longer span 
would have reduced too much the sample, while a smaller span would have been able 
only to find short-term effects, therefore not capturing effects on CVD hospitalization, 
that are thought to happen in the medium and long-term. 
The Probit model adopts hospitalization as a dependent variable and speed of 
recovery () plus a set of socio-economic and health characteristics as control 
variables. Between dependent variable and covariates there exists a one-year lag, to 
ensure that medium and long-term effects on hospitalization are captured.  We repeat 
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this analysis for the subset of patients in primary prevention in order to understand the 
impact on individuals who are using statins as a preventative therapy.  
Results of these analyses are reported in Table 4. Looking at the elasticity column, 
we observe that a 10% increase in the speed of recovery (i,t) is able to reduce the 
hospitalization rate by 1%. Less significant results are found in the other control 
variables, there being a small gender effect (men are slightly more likely to go to the 
hospital) but no significant geographical effects. As expected, patients in secondary 
prevention were more likely to be hospitalized. When looking at the primary 
prevention subset, we find slightly stronger and more significant results for 
hospitalization reduction (the elasticity effect being above 1.2%) with the other 
coefficients being similar to the previous specification, although gender and 
hypertension lose their significance. This finding is particularly important as it refers 
to a class of patients that could avoid or see delayed hospitalizations for CVDs, 
reducing social costs and financial costs for the NHS. 
Based on these results, and given that the number of CVD-related admissions in 
Italy was about 1.2 million in 2006 [14], it then follows that the number of 
hospitalisations that could be saved following a minimum of 10% increase in  would 
range between 12,000 and 15,000 cases per annum. Obviously, if we could double the 
value of  (corresponding to a 100% increase)we could then save hospitalizations in 
a range of 120,000-150,000 per year, with a huge impact also on the health 
expenditure side.  
 
 
5.2 The determinants of the speed of recovery 
5.2.1. The empirical model  
In order to analyze the determinants of the speed of recovery () and to 
disentangle the specific role played by patients, physicians and technical innovation, 
we define the following empirical model where our dependent variable is regressed 
over a set of covariates: 
 
i,t = φ(LDLi,t-1, HPi,t, LSi,t, SECi,t, TRi,j,t, tt, ci) + εi,t   (5) 
 
where the lagged cholesterol level, LDLi,t-1, may help capturing faster convergence 
rates for cases with higher LDL level; HPi,t is a vector of variables defining 
the patient health profile; LSi,t is a vector of variables that refers to patient 
lifestyle; SECi,t is a vector of patient demographic and socio-economic 
characteristics; TRi,j,t refers to the j-th active ingredient taken by the i-th 
patient; tt is a time trend to capture improvements in the speed of recovery that 
are not otherwise captured by the other ariables; ci,t is a cohort dummy 
representing the year (cohort) in which patients have started the therapy with 
statins. Time and cohort variables represent residual effects, which are not 
captured by the other covariates and will capture doctors’ input in terms of 
effort and ability, which is usually difficult to determine directly. Finally, εi,t is 
a standard additive idiosyncratic error term normally distributed.  
The first four variables in eq. (5) are intended to capture patient behaviour, while 
TRi,j,t and tt account for exogenous technical change. Concerning patient health 
profiles, the HPi,t vector contains a dummy controlling for the presence of past CVD 
events (primary vs. secondary prevention) and additional dummy variables 
controlling for hypertension and diabetes. The vector LSi,t controls for smoking 
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behaviour, while the vector SECi,t includes age, gender, region of residence and 
exemption typology. In this model we use a principal-agent framework, thus assuming 
that only physicians can decide what to prescribe and whether to switch patients to a 
new therapy; whereas patient decisions are limited to adhering or not to the proposed 
treatments and to adopt or not lifestyle advices. Patient decisions may be independent 
of the therapy suggested, but influenced by other individual-specific factors (i.e. 
economic variables such as disposable income Ydi,t and drug price pt that negatively 
affect patient adherence to treatment). 
 
 
5.2.2 Results 
Results are presented in Table 5 and are based on different empirical 
specifications of the model in eq. (5). All estimates are based on a random-effects 
model with the addition of group-means of the independent variables, according to the 
Mundlak specification [15].This specification allows us to use random-effects in a 
context where we cannot assume that covariates and individual effects are 
uncorrelated. At the same time, we cannot use a fixed-effects specification because it 
would imply dropping some of the time-invariant variables that are essential for our 
model, i.e. the cohort dummies
6
. In our model, the reference patient is a male, aged 
below 50 years, living in the Centre (i.e. the central regions of Italy), treated with 
Fluvastatin, non-smoker, not exempt from prescription charges, with no co-
morbidities and in primary prevention.  
As expected, speed of recovery is positively related with patient lagged 
cholesterol level, LDLi,t-2. A higher past cholesterol level is associated with a quicker 
reduction of the health gap. Looking at the role of technical progress in terms of 
“product” innovation our results show that “second generation” statins (i.e. 
Atorvastatin and Rosuvastatin) are found to be more effective than the alternatives. A 
smaller, but still significant role is played by Simvastatin, which belongs to the “first 
generation” group and still holds an important share of the Italian market (around 
30% in 2005, the last available year of our data, Table 6). 
The role played by “process” innovation is captured by the cohort dummies. 
These parameters show an increase in the speed of recovery by cohort. Cohort 
dummies can be thought as “residual effects” à la Solow, in a model where we 
control for a variety of factors linked to patients or to technology, such as for instance 
individual characteristics and typology of treatment. Interpreting these “residual 
effects” as doctors’ exogenous contribution is therefore a consequence of the 
covariates included in the specification, being aware that we do not have a direct 
measure of their “ability to treat”, an effect that, in general, is problematic to measure.  
By looking at the distribution of statin prescriptions by cohort (Table 6), we 
observe how there exist systematic differences between people belonging to different 
cohorts, within a common year of the sample. For instance, in 2005 the 2001 cohort 
received Simvastatin in about 35% of cases, while the 2005 cohort, in the same year, 
received Simvastatin in only 28% of cases. More importantly, Rosuvastatin (the most 
innovative product at the time) was prescribed to 9.5% of the 2001 cohort, while the 
2005 cohort received the same active ingredient in 20% of the cases. This shows a 
                     
6
 In the estimation phase, we have tried two specifications, one adding individual-means covariates 
with within-variance greater than 33% and the other controlling for mean variables with within-
variance greater than 40%, in order to avoid multi-collinearity problems. Results are consistent 
between the two specifications, but we decided to use the one with a 33% bar as it is less restrictive. 
Estimates have been produced using the command mundlak in STATA. 
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certain degree of conservativeness from doctors in treating patients who started the 
treatment with statins earlier, as they are kept using older generation and less effective 
statins. On the other side, later cohorts would be expected to receive a boost in terms 
of lowering LDL levels as they are using, on average, more advanced drugs.  
Looking at patient behaviour, we see that persistence to the treatment is found to 
be consistently significant. We also find a strong positive association between speed 
of recovery and being in secondary prevention. It seems that patients who have 
experienced a serious cardiovascular event or are experiencing co-morbidities are, 
understandably, more careful, thus showing a faster recovery. Finally, a less 
significant but still positive association is found between speed of recovery and being 
hypertensive. 
The impact of smoking on the speed of recovery is found to be negative but not 
significant. The sign direction is as expected, while the non-significance could be due 
to an extremely low rate of smokers in the sample.  
 The alternative specifications seem to confirm the results so far described. In 
model 2 we included as a further control the prescribed daily dosage (in terms of 
milligrams of active ingredient), in order to separate the compound effect from the 
dosage effect. This aspect is not entirely trivial, as physicians can use an older statin 
with an increased dosage, potentially getting the same effect of a newer compound at 
a reduced dosage. The results from this specification provide additional evidence of 
the positive effect that a higher dosage has on the speed of recovery. Looking at the 
active ingredient indicators, we observe that the “hierarchy” between the compounds’ 
effectiveness remains unchanged and it is fairly stable in terms of proportions. 
In model 3 we added the interaction terms between active ingredient and daily 
dosage. In this case the daily dosage loses part of its significance, while the size of the 
coefficient is almost unaltered, although Simvastatin loses its significance.  
In model 4 we added the interactions between the cohort dummies and a linear 
time trend, introducing a set of parameters that could help replicate the patterns found 
in figure 2. For each cohort, each interaction term can be seen as a differential effect 
on the speed of recovery with respect to the treatment starting year. According to this 
interpretation, the sign and magnitude of all interaction parameters seem to replicate 
correctly the patterns of the unconditional means reported in Table 1 and Figure 2. In 
particular, the interactions for the 2002 and 2003 cohorts suggest an increasing trend, 
which make them benefit from having an additional effect with respect to the cohort 
standard effect. With regards to the 2004 cohort, such an increasing trend does not 
appear, but both cohort and interactions are significant at 1%. An exception is 
represented by the 2005 cohort, whose only time interaction variable is found to be 
high in magnitude but not significant. 
As a robustness check, we have investigated the role of attrition in our sample and 
how it affects our estimates by re-weighting the observations according to their drop-
out probability [16]. Overall, we found that our results are not affected by attrition 
(the estimates are available upon request to the authors). 
 
 
5.3 – Who is responsible for your health? A quantitative assessment 
We are now in a position to provide an answer to our initial question: who is 
responsible for your health. In order to achieve this goal we calculate the impact of 
the three factors (patients, doctors or technology) over the predicted values of lambda, 
the speed of recovery.  
The role of patients is approximated using the persistency variable; the role of 
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doctors is captured by the cohort dummy parameters, while medical technology 
impact is represented by the active ingredient dummies.  
Results of this accounting exercise are presented in Table 7. In the first 
specification, where we are not controlling for the drug dosage, medical behaviour 
present a greater impact than technology (around 49% vs. 38%), while the role of 
patients appears to be minor. After controlling for drug dosages in specification 2 and 
3, technology becomes by far the most important factor.  
This result is also confirmed in the last two specifications, when interactions 
between cohorts and the time-trend are added. The effect of technology ranges 
between 54% and 68%. The role of doctors appears to be greater than the role of 
patients in all the specifications considered. 
As a further check, separate computations of the effects for men and women (not 
reported here) have shown that gender issues do not significantly affect the relative 
importance of the three factors. 
Our findings suggest that the use of drugs is the only effect, which prevails 
steadily. This is not surprising, as doctors and patients effort is to be thought as 
conditioned on the available pharmacological therapies. However, our estimates seem 
to prove that technology explains just above two-thirds (at best 68%) of the speed of 
recovery to a better health status, with its efficacy mediated by physician and, to a 
lesser extent, patient behaviours. 
 
 
6. Conclusion 
Focusing on patients suffering from hypercholesterolemia and treated with statin-
based drugs, in this work we have analysed the determinants of a better health status, 
trying to disentangle the roles played by patients, physicians and technology, and how 
a faster recovery is reflected in terms of reduction in hospitalization rates. Our results 
show that the speed of recovery is capable of reducing future hospitalization rates: 
better-treated patients experience lower hospitalization rates for CVDs (from 1% for 
the general sample to more than 1.2% for patients in primary prevention). 
More importantly, we found that treatments with newer drugs, even after 
controlling for dosage, leads to a faster recovery to better health conditions. However, 
this effect could be seriously undermined if patients are not persistent in the treatment. 
Finally, there is a suggestion that a reduced prescription of newer drugs from GPs to 
longer-lasting treated patients may have a role in their slower recovery. In this respect, 
we found some evidence of a certain degree of conservativeness in GPs, who tended 
to persist in the use of older statins for the long-term treated group.  
From an accounting exercise, we observe that technology, although being the 
driving factor in increasing the speed of recovery, can explain at best 68% of the total 
effect, which reduces to 54% in the richer specification.  
In conclusion, the evidence obtained from this work sheds light on the importance 
of technical progress (both in terms of product and process innovation) for a full and 
faster health recovery for patients suffering from hypercholesterolemia, which could 
be even more effective if this technical advancement was made immediately available 
to all patients.  
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Figure 1 
Trends and distributions of cholesterol levels 
in the Health Search population 
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Source: Our calculation, based on HSD data. 
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Figure 2 
Mean LDL cholesterol by cohort 
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Figure 3 
Possible patterns of cholesterol trends 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17 
 
 
 
Table 1 – LDL statistics by cohort 
 
Panel A 
Average LDL levels by year 
Year 
Cohort 
2001 2002 2003 2004 2005 
2001 162.6 - - - - 
2002 139.3 153.2 - - - 
2003 134.9 130.6 148.2 - - 
2004 132.0 126.3 125.4 143.2 - 
2005 128.0 123.0 120.4 118.3 136.2 
2006 127.0 123.6 118.7 114.4 114.6 
Panel B 
Changes in average LDL levels by year 
Year 
Cohort 
2001 2002 2001 2004 2001 
2001 - - - - - 
2002 -14.3% - - - - 
2003 -3.1% -14.8% - - - 
2004 -2.2% -3.3% -15.4% - - 
2005 -3.0% -2.6% -4.0% -17.4% - 
2006 -0.8% 0.5% -1.4% -3.3% -15.9% 
Average % -4,7% -5,0% -6,9% -10,4% -15,9% 
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Table 2 - Descriptive statistics for the full sample 
 
Variable Obs. Mean Std. Dev. Min. Max. 
  21188 0.131 0.642 -3.6 4.0 
Log LDL (t-2) 21188 4.972 0.244 4.0 6.1 
Male 21188 0.509 0.500 0 1 
Age Class 39-50 21188 0.049 0.215 0 1 
Age Class 50-60 21188 0.230 0.421 0 1 
Age Class 60-70 21188 0.484 0.500 0 1 
Age Class 70+ 21188 0.237 0.425 0 1 
North-West 21188 0.247 0.431 0 1 
North-East 21188 0.260 0.439 0 1 
Centre 21188 0.147 0.354 0 1 
South 21188 0.235 0.424 0 1 
Islands 21188 0.112 0.315 0 1 
Simvastatin 21188 0.319 0.466 0 1 
Pravastatin 21188 0.164 0.370 0 1 
Fluvastatin 21188 0.119 0.323 0 1 
Atorvastatin 21188 0.310 0.463 0 1 
Rosuvastatin 21188 0.088 0.284 0 1 
Hypertensive 21188 0.594 0.491 0 1 
Diabetes 21188 0.287 0.452 0 1 
Secondary prevention 21188 0.094 0.291 0 1 
Persistent 21188 0.702 0.457 0 1 
Cohort 2001 21188 0.175 0.380 0 1 
Cohort 2002 21188 0.410 0.492 0 1 
Cohort 2003 21188 0.250 0.433 0 1 
Cohort 2004 21188 0.135 0.342 0 1 
Cohort 2005 21188 0.030 0.171 0 1 
Smoker 21188 0.017 0.130 0 1 
Drug milligrams 21188 27.449 20.088 0 1 
Exemption: Age 21188 0.279 0.449 0 1 
Exemption: CVD 21188 0.100 0.300 0 1 
Exemption: Invalidity 21188 0.059 0.236 0 1 
Exemption: Income 21188 0.048 0.213 0 1 
Doctor is a female 21188 0.119 0.324 0 1 
Doctor’s age 21188 50.711 4.035 35 67 
Year 2002 21188 0.084 0.277 0 1 
Year 2003 21188 0.229 0.420 0 1 
Year 2004 21188 0.309 0.462 0 1 
Year 2005 21188 0.284 0.451 0 1 
Year 2006 21188 0.094 0.291 0 1 
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Table 3 - Sample means by cohort for the full sample 
 
Variable 
  
Cohort 
2001 2002 2003 2004 2005 
  0.113 0.207 0.219 0.360 0.384 
Initial LDL 166.0 170.1 170.4 167.6 161.8 
Target LDL 102.0 102.2 101.1 99.1 98.5 
LDL (t-1) 149.5 149.3 146.9 145.2 145.9 
LDL (t-2) 150.6 152.5 152.1 153.0 156.0 
Hospitalized 0.008 0.012 0.008 0.012 0.015 
Patients reaching target 0.063 0.101 0.110 0.160 0.155 
Male 0.483 0.468 0.473 0.512 0.507 
Age 63.4 62.9 63.1 63.3 62.7 
North-West 0.255 0.251 0.233 0.233 0.209 
North-East 0.238 0.239 0.247 0.245 0.233 
Centre 0.203 0.128 0.137 0.154 0.139 
South 0.179 0.264 0.274 0.254 0.274 
Islands 0.124 0.117 0.109 0.114 0.145 
Hypertensive 0.493 0.571 0.594 0.637 0.675 
Diabetes 0.227 0.232 0.255 0.321 0.400 
Secondary prevention 0.066 0.107 0.079 0.098 0.131 
Persistent 0.582 0.564 0.640 0.715 0.634 
No. Patients 474 1396 1148 933 339 
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Table 4 - Hospitalization probability 
 
 
Full Sample 
 
Primary prevention 
 
Variable Coefficient Elasticity Coefficient Elasticity 
1t  -0.271** -0.098 -0.347*** -0.125 
LDL t-1 -0.119 -1.507 -0.256 -3.314 
Male 0.196* 0.245 0.169 0.210 
Age class 50-60 -0.015 -0.010 0.036 0.023 
Age class 60-70 0.074 0.096 0.137 0.182 
Age class 70+ -0.015 -0.007 0.008 0.004 
North-West -0.012 -0.007 0.129 0.081 
North-East 0.086 0.054 0.117 0.074 
South 0.218 0.084 0.357 0.143 
Islands 0.170 0.108 0.295 0.191 
Hypertensive t-1 0.252** 0.352 0.208 0.295 
Diabetes t-1 0.103 0.065 0.011 0.007 
Secondary prevention t-1 0.609*** 0.123 -  
Cohort 2001 -0.130 -0.111 -0.1524 -0.130 
Cohort 2002 -0.071 -0.049 -0.049 -0.034 
Cohort 2003 -0.022 -0.010 -0.093 -0.045 
Cohort 2004 0.011 0.001 -0.089 -0.010 
Constant -1.926  -1.302  
No. Patients 3316  3052  
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Table 5 -Mundlak Random-Effects panel estimates 
Variable Model 1 Model 2 Model 3 Model 4 Model 5 
Log LDL (t-2) 0.884*** 0.885*** 0.885*** 0.961*** 0.961*** 
Male -0.01 -0.013 -0.013 -0.015 -0.016 
Age class 50-60 -0.033 -0.033 -0.033 -0.038 -0.039 
Age class 60-70 -0.015 -0.015 -0.014 -0.034 -0.034 
Age class 70+ 0.008 0.007 0.008 -0.029 -0.029 
North-West -0.023 -0.016 -0.014 -0.013 -0.012 
North-East -0.017 -0.009 -0.006 -0.006 -0.008 
South 0.017 0.024 0.027 0.029 0.028 
Islands 0.026 0.026 0.027 0.029 0.026 
Simvastatin 0.051** 0.216*** 0.128 0.121 0.121 
Pravastatin -0.037 0.113*** 0.052 0.043 0.042 
Atorvastatin 0.127*** 0.325*** 0.207** 0.192** 0.191** 
Rosuvastatin 0.212*** 0.430*** 0.400*** 0.365*** 0.363*** 
Hypertensive 0.019 0.018 0.018 0.007 0.008 
Diabetes -0.054*** -0.056*** -0.056*** -0.063*** -0.064*** 
Secondary prevention 0.106*** 0.101*** 0.100*** 0.087*** 0.087*** 
Persistent 0.035* 0.035* 0.035* 0.039** 0.039** 
Cohort 2002 0.080*** 0.078*** 0.078*** -0.009 -0.007 
Cohort 2003 0.096*** 0.092*** 0.091*** 0.007 0.007 
Cohort 2004 0.178*** 0.174*** 0.174*** 0.104*** 0.103*** 
Cohort 2005 0.213*** 0.211*** 0.210*** 0.205*** 0.203*** 
Smoker -0.019 -0.018 -0.018 -0.018 -0.018 
Exemption: Age -0.095*** -0.096*** -0.095*** -0.074*** -0.074*** 
Exemption: CVD 0.064** 0.061** 0.061** 0.052** 0.052** 
Exemption: Invalidity 0.027 0.028 0.028 0.018 0.018 
Exemption: Income 0.039 0.039 0.039 0.018 0.018 
Drug milligrams  0.003*** 0.002** 0.002* 0.002* 
Simvastatin x mg   0.002 0.001 0.001 
Pravastatin x mg   0.001 0.001 0.001 
Atorvastatin x mg   0.004 0.004 0.004 
Rosuvastatin x mg   -0.003 -0.004 -0.004 
Cohort 02 x year 03    0.072*** 0.071*** 
Cohort 02 x year 04    0.093*** 0.091*** 
Cohort 02 x year 05    0.145*** 0.141*** 
Cohort 02 x year 06    0.176*** 0.171*** 
Cohort 03 x year 04    0.089*** 0.087*** 
Cohort 03 x year 05    0.121*** 0.118*** 
Cohort 03 x year 06    0.174*** 0.170*** 
Cohort 04 x year 05    0.116*** 0.115*** 
Cohort 04 x year 06    0.111*** 0.109*** 
Cohort 05 x year 06    0.049 0.047 
Doctor is female     0.003 
Doctor’s age     0.001 
Constant -0.159 -0.393 -0.311 -0.31 -0.373 
       
No. Observations 21188 21188 21188 21188 21188 
No. Patients 4290 4290 4290 4290 4290 
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Table 6 - Distribution of statins prescriptions by cohort 
 (Sample Year 2005) 
Active Ingredient 2001 2002 2003 2004 2005 
Simvastatin 34.5% 34.4% 32.4% 27.0% 27.8% 
Pravastatin 17.8% 16.8% 18.8% 16.2% 12.7% 
Fluvastatin 47% 8.5% 9.2% 7.0% 7.3% 
Atorvastatin 33.5% 31.2% 30.6% 31.9% 31.8% 
Rosuvastatin 9.5% 9.1% 9.1% 18.0% 20.5% 
No. Observations 8735 19517 18703 22860 17861 
 
 
 
 
Table 7 - Estimated importance of patients, technology and doctors in determining speed of 
recovery 
Model Specification Model 1 Model 2 Model 3 Model 4 Model 5 
Patient behaviour 13.6% 7.3% 9.5% 10.7% 10.8% 
Technology 37.9% 67.5% 57.8% 53.8% 53.9% 
Medical behaviour 
48.5% 25.3% 32.7% 35.4% 35.3% 
 
 
 
 
 
 
 
 
 
 
 
 
